Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RBMRNA-176 in Healthy Adults
NCT05903118Phase 2Completed
- Sponsor
- Argorna Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RBMRNA-176 in coronavirus disease 2019 (COVID-19), sponsored by Argorna Pharmaceuticals. Started Jan 2022; status: completed.
02
Drugs
RBMRNA-176
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05903118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05903118.